News and Events

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

27 January 2023

This recent study describes the recurrence risk, progression patterns, response to subsequent treatment, and survival of patients with advanced melanoma who ceased targeted therapy prior to disease progression. It concludes that the risk of progression after cessation of targeted therapy is strongly associated with treatment duration. Response to retreatment with targeted therapy is high.

Worldwide usable matrix of UV radiation exposure in occupations to foster epidemiological and legislative efforts to combat nonmelanoma skin cancer

27 January 2023

The objective of this recent study was to build a worldwide usable matrix of UV radiation exposure in occupations and to show use cases for the data. It hopes to enable sound studies on the nature of UV-induced skin cancer, dose–response relationships, intermittency of skin exposure, and derivation of limit values and to make sociological studies on prevention possible. Practitioners may use the findings for their daily work with employees.

Keynote-716: Overall benefit–risk of pembrolizumab continues to be positive in adjuvant setting

14 January 2023

Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial. Here, authors report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up. They conclude that the overall benefit–risk of pembrolizumab continues to be positive in the adjuvant setting.

Motivations and barriers for participating in melanoma genomics research

14 January 2023

Findings of this recent study provide new insights into the motivations for participating in genomics research and highlight the need to better target population subgroups including younger men, which will aid in tailoring recruitment for future melanoma genomic studies.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

12 January 2023

Authors of this recent study examined the efficacy of checkpoint inhibitors in acral melanoma. It concludes that while the objective response rate to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and progression-free survival numerically higher, this benefit did not translate to improved overall survival. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis

12 January 2023

This recent study concludes that in patients with melanoma brain metastasis (MBM), the addition of radiotherapy resulted in a favorable overall survival (OS) on systemic therapy. In BRAF-mutated MBM patients, immune checkpoint blockade as first-line therapy and BRAF+MEK as second-line therapy were associated with a significantly prolonged OS.